Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PUSA vs ACA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

ACA Overall Winner 6-Pillar Tally: PUSA 0 – 5 ACA (1 Tie) Matrix Metrics: PUSA 0 – 10 ACA

As of Nov 20, 2026, Arcosa, Inc. (ACA) is the stronger overall head-to-head candidate over PUSA (PUSA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PUSA carries a Unified Composite Score of 38.8/100 (SELL) at $1.12 (N/M Forward P/E, N/A operating margin), whereas ACA carries 60.0/100 (BUY) at $149.15 (29.1x Forward P/E, 12.3% operating margin).

  • Technical & Structure Timing Caution: PUSA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.2); meanwhile ACA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 82.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PUSA vs ACA
PUSA US Equity
PUSA
Institutional Equity
$1.12
+0.9% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.56β · 105% Vol
Unified Composite Score
38.8 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.7%), weak momentum, RSI 27
RSI-14: 27.2 · SMA20: $1.53 · SMA50: $2.37
ACA NYSE Head-to-Head Winner
Arcosa, Inc. Common Stock
Fabricated Structural Metal Products
$149.15
+0.08% 1D
Market Cap $7.3B
TTM Revenue $1.19B
Forward P/E 29.1x
Beta / 30D Vol 0.92β · 4% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 56.0 Fund 49.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 82
RSI-14: 82.2 · SMA20: $147.01 · SMA50: $146.08

6-Pillar Scorecard Institutional Category Breakdown (PUSA 0 – 5 ACA)

Columns: Metric · PUSA · ACA
1. Valuation Multiples ACA
Forward P/E N/M 29.1x
Trailing P/E N/M 36.4x
PEG Ratio N/M 1.86x
EV / Revenue N/M 6.1x
2. Growth & Scale ACA
Revenue Growth (YoY) N/A +1.7%
Earnings Growth (YoY) N/A +448.6%
TTM Revenue (USD) N/A $1.19B
Market Cap N/A $7.3B
3. Profitability & Quality ACA
Gross Margin N/A 22.8%
Operating Margin N/A 12.3%
Net Profit Margin N/A 16.8%
Return on Equity (ROE) N/A 8.0%
4. Balance Sheet & Cash Flow ACA
Cash Generation (TTM) N/A $224M EBITDA
Cash Flow Margin N/A 18.8% EBITDA Mgn
Net Cash / Leverage N/A ROE $60.76 Book/Sh · 8.0% ROE
Dividend Yield None (0.00%) 0.14%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 28.7% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ACA
OpEx & R&D Intensity N/A 10.5% of Rev ($125M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Engineering & Construction Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PUSA (0) vs ACA (10)
Institutional Metric PUSA ACA Criterion Row Edge
Market Capitalization
Scale
N/A $7.3B Larger Scale ACA
Trailing P/E Ratio
Valuation
N/M 36.4x Lower Multiple ACA
Forward P/E Ratio
Valuation
N/M 29.1x Lower Multiple ACA
Revenue Growth (YoY)
Growth
N/A +1.7% Higher Growth ACA
Operating Margin (TTM)
Profitability
N/A 12.3% Higher Margin ACA
Net Profit Margin
Profitability
N/A 16.8% Higher Margin ACA
Return on Equity (ROE)
Capital Efficiency
N/A 8.0% Higher ROE ACA
52-Week Range Position
Momentum
2% ($1–$7) 100% ($91–$149) Stronger Trend ACA
Beta / 30D Volatility
Risk Regime
1.56β · 105% Vol 0.92β · 4% Vol Lower Realized Risk ACA
Unified Institutional Score
Composite Signal
38.8 / 100 (SELL) 60.0 / 100 (BUY) Higher Composite ACA
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.19B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 22.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.86x PEG · 6.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $224M EBITDA ($60.76 Book/Sh · 8.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACA +48.84 pp
PUSA: -47.03% · ACA: +1.81%
3M Horizon ACA +41.99 pp
PUSA: -39.13% · ACA: +2.86%
6M Horizon ACA +76.86 pp
PUSA: -54.73% · ACA: +22.13%
1Y Horizon ACA +76.86 pp
PUSA: -54.73% · ACA: +22.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PUSA vs ACA. Trailing 12-month operating profitability (PUSA N/A vs ACA 12.3%) and valuation multiples (PUSA N/M vs ACA 29.1x Forward P/E) are benchmarked directly in Pillar 4 below.

PUSA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ACA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.19B
Gross Margin22.8%
Op. Margin12.3%
ROE / Fwd P/E8.0% · 29.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PUSA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PUSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.7%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PUSA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACA Moat Profile Cyclical / Execution-Driven Positioning
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $7.3B market capitalization and 12.3% operating margin.
OpEx & R&D Reinvestment 10.5% of Rev ($125M)
90D Engineering Disclosures 0 Published

Investor FAQ PUSA vs ACA Key Questions & Quantitative Answers

As of Nov 20, 2026, Arcosa, Inc. (ACA) is the stronger overall head-to-head candidate over PUSA (PUSA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PUSA carries a Unified Composite Score of 38.8/100 (SELL) at $1.12 (N/M Forward P/E, N/A operating margin), whereas ACA carries 60.0/100 (BUY) at $149.15 (29.1x Forward P/E, 12.3% operating margin). Technical & Structure Timing Caution: PUSA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.2); meanwhile ACA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 82.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACA leads the Growth & Scale pillar: PUSA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACA at +1.7% YoY revenue growth and +448.6% YoY earnings growth on $1.19B TTM revenue (22.8% gross margin, 12.3% operating margin). On trailing 12-month operating scale, PUSA generates N/A in USD-normalized revenue versus $1.19B for ACA. In operating R&D and SG&A reinvestment, PUSA deploys N/A (0 90-day corporate R&D disclosures) versus 10.5% of Rev ($125M) (0 disclosures) for ACA.

ACA screens cheaper on headline valuation multiples. PUSA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACA trades at 29.1x Forward P/E, 36.4x Trailing P/E, 1.86x PEG, and 6.1x EV/Revenue (18.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PUSA (N/A ROE) versus ACA (8.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PUSA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 105% Vol realized risk). By comparison, ACA carries 28.7% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.